Omrix Biopharmaceuticals, a Johnson & Johnson company, specializes in developing and manufacturing life-saving products based on human plasma. Their patented technology is used to create advanced biotechnological and human-plasma-based products that help control bleeding during surgery and improve the quality of life for people with immune deficiencies. Founded in 1995, Omrix went public on the US Stock Exchange in 2006 and was acquired by Johnson & Johnson two years later. Today, Omrix reports through ETHICON, Medical Device & Diagnostics unit at Johnson&Johnson, and has over 500 employees in Israel. Omrix provides a home for their employees, where they can leave a mark in the medical world of tomorrow.